Previous 10 | Next 10 |
2024-07-13 14:03:47 ET More on Amgen, Biogen, etc. Biogen's Diverse Drug Portfolio Faces Competitive Challenges In 2024 Merck: Positive Developments, But Watch The Q2 Earnings Biogen Stock: Cheapish, But With Few Growth Prospects This weight loss stock is the...
2024-07-12 10:50:24 ET Read the full article on Seeking Alpha For further details see: These are the weight loss drug stocks with the most upside - SA Sentiment Survey
2024-07-12 10:27:31 ET More on Novo Nordisk Novo Nordisk: Buy On Dips Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk once-weekly insulin rejected by FDA ...
2024-07-12 04:12:28 ET More on Amgen Amgen: Biotech Leader Riding High On Obesity Drug Euphoria (Downgrade) Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum Amgen: You Haven't Seen Anything Yet Lilly, Novo Nordisk to dominate weight lo...
2024-07-11 14:19:51 ET Summary Pfizer Inc. announced today that it planned to continue development of its GLP-1 agonist weight loss drug danuglipron as a once-daily oral pill. The drug met efficacy endpoints in a Phase 2 study last year as a twice daily pill, but side effects caus...
2024-07-11 13:19:08 ET More on Novo Nordisk Novo Nordisk: Buy On Dips Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Most patients discontinue Novo’s Wegovy, Ozempic ...
2024-07-11 07:18:20 ET Buoyed by encouraging pharmacokinetic data from an ongoing study, Pfizer ( NYSE: PFE ) has decided to proceed with the development of a once-daily formulation of its oral weight-loss drug, danuglipron.... Read the full article on Seeking Alpha ...
2024-07-10 08:25:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy lagged sl...
2024-07-10 08:19:40 ET More on Novo Nordisk Novo Nordisk: Buy On Dips Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Study finds patients lost more weight on Mounjaro than O...
2024-07-09 22:22:11 ET Summary VIGI has underperformed due to market-wide preference for US mega-cap stocks, but valuation and diversification may lead to mean reversion favoring VIGI. 2Q is expected to mark the first growth quarter for "Other" 493, a potential catalyst for change...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...
2024-07-13 17:52:00 ET Novo Nordisk (NYSE: NVO) is already a stock that's easy to justify buying. Between the incredible success of Ozempic, tons of demand for its weight loss medicine, and big investments in manufacturing as well as its pipeline, optimism about its future is practi...